The estimated Net Worth of Qasim Rizvi is at least $1.68 million dollars as of 31 December 2020. Mr. Rizvi owns over 7,337 units of Kiniksa Pharmaceuticals International Plc stock worth over $178,583 and over the last 5 years he sold KNSA stock worth over $0. In addition, he makes $1,503,570 as Senior Vice President - Operations et Chief Commercial Officer at Kiniksa Pharmaceuticals International Plc.
Sign up
Mr. Rizvi KNSA stock SEC Form 4 insiders trading
Qasim has made over 1 trades of the Kiniksa Pharmaceuticals International Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,337 units of KNSA stock worth $178,583 on 31 December 2020.
The largest trade he's ever made was exercising 7,337 units of Kiniksa Pharmaceuticals International Plc stock on 31 December 2020 worth over $178,583. On average, Qasim trades about 1,467 units every 0 days since 2019. As of 31 December 2020 he still owns at least 7,337 units of Kiniksa Pharmaceuticals International Plc stock.
You can see the complete history of Mr. Rizvi stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Qasim Rizvi biography
Qasim Rizvi serves as Senior Vice President - Operations, Chief Commercial Officer of the Company. Prior to that, Dr. Rizvi served in roles of increasing responsibility at Genentech, Inc. ("Genentech"), a member of the Roche Group, or Roche, having joined the company in June 2006. From October 2017 to August 2018, Dr. Rizvi served as Genentech's Vice President and U.S. Franchise Head of Tecentriq, with commercial responsibilities for Genentech's Cancer Immunotherapy portfolio. From September 2016 to October 2017, Dr. Rizvi served as Vice President—Franchise Head Hematology; Global Product Strategy at Roche, where he led the global hematology franchise. From October 2014 to September 2016, Dr. Rizvi served as Life Cycle Leader at Genentech, where he was responsible for bringing Roche's Hemophilia product from Phase 1b to the global commercialization. Prior to joining Genentech/Roche, Dr. Rizvi was at Novo Nordisk and Eli Lilly, where he served in numerous roles in sales, marketing, business development and new product planning. Dr. Rizvi received his medical degree from the University of Dundee School of Medicine. He completed his residency in general surgery and holds an M.B.A in Marketing and Corporate Strategy from the University of Michigan's Stephen M. Ross School of Business.
What is the salary of Qasim Rizvi?
As the Senior Vice President - Operations et Chief Commercial Officer of Kiniksa Pharmaceuticals International Plc, the total compensation of Qasim Rizvi at Kiniksa Pharmaceuticals International Plc is $1,503,570. There are 2 executives at Kiniksa Pharmaceuticals International Plc getting paid more, with Sanjiv Patel having the highest compensation of $4,765,670.
How old is Qasim Rizvi?
Qasim Rizvi is 50, he's been the Senior Vice President - Operations et Chief Commercial Officer of Kiniksa Pharmaceuticals International Plc since 2019. There are 10 older and 3 younger executives at Kiniksa Pharmaceuticals International Plc. The oldest executive at Kiniksa Pharmaceuticals International Plc. is Barry Quart, 63, who is the Independent Director.
What's Qasim Rizvi's mailing address?
Qasim's mailing address filed with the SEC is CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON, D0, HM 11.
Insiders trading at Kiniksa Pharmaceuticals International Plc
Over the last 7 years, insiders at Kiniksa Pharmaceuticals International Plc have traded over $11,259,873 worth of Kiniksa Pharmaceuticals International Plc stock and bought 3,912,796 units worth $71,248,379 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., James E Deerfield Mgmt L.P.... et Bros. Advisors Lp667, L.P.B.... On average, Kiniksa Pharmaceuticals International Plc executives and independent directors trade stock every 22 days with the average trade being worth of $1,208,067. The most recent stock trade was executed by Eben Tessari on 1 September 2024, trading 6,463 units of KNSA stock currently worth $157,309.
What does Kiniksa Pharmaceuticals International Plc's logo look like?
Complete history of Mr. Rizvi stock trades at Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals International Plc executives and stock owners
Kiniksa Pharmaceuticals International Plc executives and other stock owners filed with the SEC include:
-
Sanjiv Patel,
Chairman of the Board, Chief Executive Officer -
John Paolini,
Senior Vice President and Chief Medical Officer -
Qasim Rizvi,
Senior Vice President - Operations, Chief Commercial Officer -
Sanj K. Patel,
CEO & Chairman -
Richard Levy,
Independent Director -
Felix Baker,
Lead Independent Director -
Thomas Malley,
Independent Director -
Barry Quart,
Independent Director -
Stephen Biggar,
Independent Director -
Tracey McCain,
Independent Director -
Kimberly Popovits,
Independent Director -
G. Bradley Cole,
Director -
Thomas Beetham,
Executive Vice President, Chief Legal Officer and Corporate Development, and Secretary -
Michael Megna,
Principal Financial Officer, Chief Accounting Officer -
Dr. John F. Paolini,
Sr. VP & Chief Medical Officer -
Mei Jang,
VP of Technical Operations -
Michael R. Megna,
Chief Accounting Officer & VP of Fin. -
Christine Maurer,
Sr. VP of Program Management -
Carsten Boess,
Exec. VP of Corp. Affairs -
Rasmus Holm-Jorgensen,
Sr. VP, Chief Strategy & Portfolio Officer -
Melissa Manno,
Chief HR Officer -
Madelyn Zeylikman,
Gen. Counsel -
Chad Morin,
VP & Chief Compliance Officer -
Mark Ragosa C.F.A.,
Sr. VP & CFO -
Bros. Advisors Lp667, L.P.B...,
-
Asset Management, Lp Chen B...,
-
Stephen F. Mahoney,
President & COO -
James E Deerfield Mgmt L.P....,
-
Carsten Boess,
10% owner -
Chris Heberlig,
EVP & CFO -
Sanj K Patel,
CHAIRMAN & CEO -
Ross Moat,
CHIEF COMMERCIAL OFFICER -
Mark Ragosa,
CHIEF FINANCIAL OFFICER -
Eben Tessari,
CHIEF OPERATING OFFICER -
Arian Pano,
Chief Clinical Dev. Officer